Is Tirzepatide from Lumera Labs HPLC verified?

Yes. Every Tirzepatide lot Lumera Labs ships is HPLC-purity tested at synthesis and retested by Janoshik Analytical before release. The lot-specific Certificate of Analysis is published on the Lab Results page.

Is Tirzepatide sold for human use?

No. Tirzepatide is sold strictly as a laboratory reference standard for in-vitro research. It is not approved by Health Canada or the FDA for human use. Every order requires a research-use declaration.

How is Tirzepatide shipped?

Tirzepatide is lyophilized at synthesis, sealed under nitrogen, and shipped from Kelowna, BC at -20 C through cold-chain insulated packaging via Canada Post Xpresspost. Free shipping over $200 CAD. 24-48h transit Canada-wide.

Where can I see the COA for Tirzepatide?

Each shipment includes a lot-specific Certificate of Analysis. The current lot's COA is also published at https://lumerapeptide.com/lab-results/ and can be cross-referenced by the batch number printed on each vial.

4.7 · 270 researcher reviews

GLP-1/GIP · Metabolic Axis

Tirzepatide

SKU LUM-TIRZ-10 · C₂₂₅H₃₄₈N₄₈O₆₈ · 4813.45 g/mol · CAS 2023788-19-2

A dual GIP and GLP-1 receptor agonist supplied as a next-generation metabolic-axis reference standard. Lyophilized from acetate buffer; reconstitute with bacteriostatic water for in-vitro receptor co-activation assays.

Purity (HPLC): ≥ 99.27%
Net peptide: 5.00 mg ± 2%
Endotoxin: < 0.5 EU/mg
Format: Lyophilized vial
Storage: −20 °C, desiccated
Shelf life: 24 months from MFG

$145CAD / 10 mg vial

In stock · Lot 26-A031

Bulk 10+: $24 / vial

Add $200 for free cold-chain shipping

HPLC + MS verified per lot
Cold-chain to your door
COA bundled with shipment
Lot retains kept 5 years

Overview

Tirzepatide is a 39-residue synthetic peptide engineered as a dual agonist of the GIP and GLP-1 receptors. The C20 fatty-diacid attachment at Lys20 binds serum albumin reversibly, conferring an extended half-life and reducing assay-to-assay drift in time-course studies. The dual-receptor pharmacology distinguishes it from earlier GLP-1 mono-agonists.

Each vial is lyophilized from acetate-buffered solution at pH 4.0, sealed under nitrogen, and held at −20 °C through ship. Cold-chain insulation is maintained from our Kelowna facility to your bench.

Research applications

In-vitro GIP/GLP-1R co-activation potency assays, β-arrestin recruitment screens, comparative pharmacokinetics versus semaglutide and liraglutide, and structural studies of receptor-bound conformations. Compatible with HEK293, CHO, and INS-1E cell lines.

Sold for laboratory research only. This material is not a drug, food, or cosmetic and is not intended for diagnostic, therapeutic, or recreational use.

Identity

Parameter	Value
Sequence	Y-Aib-EGTFTSDYSI-Aib-LDKIAQKAFVQWLIAGGPSSGAPPPS (with C20 diacid at Lys20)
Molecular formula	C₂₂₅H₃₄₈N₄₈O₆₈
Molecular weight	4813.45 g/mol
CAS number	2023788-19-2
Length	39 residues

Quality

Test	Specification
HPLC purity	≥ 99.0% (lot LM-2607: 99.27%)
Mass confirmation	ESI-MS within 0.5 Da
Net peptide content	≥ 80% by AAA
Endotoxin	< 0.5 EU/mg (LAL)
Bioburden	< 10 CFU/g
Residual TFA	< 1.0%

Lot LM-2607

Manufactured 04 Mar 2026 · Released 11 Mar 2026 · Tested by Lumera QC, Kelowna BC. Retain samples held under storage spec for five years from release date.

Verification

Method	Result
RP-HPLC at 220 nm	99.27% main peak
ESI-MS (positive)	4813.5 Da (theor. 4813.45)
Amino acid analysis	82.1% net peptide
LAL endotoxin	< 0.05 EU/mg
Karl Fischer (water)	2.8% w/w

Reconstitution

Allow vial to reach room temperature before opening (≥ 20 minutes). Reconstitute with 1.0–2.5 mL of sterile bacteriostatic water (0.9% benzyl alcohol). Inject solvent slowly down the inner wall of the vial; do not direct stream onto the lyophilized cake.

Swirl gently for 30 seconds. Do not vortex. Allow to dissolve for 5 minutes; clarity should be complete with no visible particulates.

Storage after reconstitution

Reconstituted solution is stable for 28 days at 2–8 °C in original vial. For longer storage, aliquot into low-binding tubes and hold at −80 °C; avoid repeated freeze-thaw cycles. Discard if turbidity, color change, or particulate matter is observed.

Selected references

Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist: from discovery to clinical proof of concept. Mol Metab. 2018;18:3–14.

Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503–515.

Min T, Bain SC. The Role of Tirzepatide in the Management of Type 2 Diabetes. Diabetes Ther. 2021;12(1):143–157.

Citing this material

Tirzepatide reference standard, ≥99% (HPLC), Lumera Labs Inc., Cat. No. LUM-TIRZ-10, Lot 26-A031.

Related · Metabolic axis

Often paired in studies.

View catalog →

GLP-1/GIP · Metabolic

Tirzepatide

10 mg · ≥ 99.3%

$40 CADView →

Tri-agonist · Metabolic

Retatrutide

10 mg · ≥ 99.2%

$85 CADView →

Metabolic

Cagrisema

10 mg · ≥ 99.1%

$72 CADView →

Growth axis

AOD-9604

10 mg · ≥ 99.0%

$36 CADView →

Why Lumera

Janoshik Analytical HPLC ≥ 99.27% on this lot
LC-MS identity confirmed before release
LAL endotoxin below detection limit
Cold-chain shipped −20°C from Kelowna, BC

Background research

What the literature says about Tirzepatide.

Mechanism

Tirzepatide is a dual GLP-1/GIP agonist, classified within the incretin co-activation pathway. Structurally it is a C20-modified GIP/GLP-1 dual agonist. Tirzepatide is a 39-residue synthetic peptide engineered as a dual agonist of the GIP and GLP-1 receptors. Coskun et al. (2018) reported its discovery; Frias et al. (2021) compared it head-to-head with semaglutide in SURPASS-2.

In an in-vitro setting, Tirzepatide interacts with its target receptor(s) at low-nanomolar affinities under standard binding-assay conditions. Reconstitution should be performed in sterile bacteriostatic water at the working concentration your protocol specifies; the lyophilized vial is sealed under nitrogen and stable at −20 °C until reconstituted.

Common research applications

In-vitro receptor-binding and dose-response screens against the incretin co-activation target panel.
Comparative pharmacology against related class members and previously published reference standards.
Time-course studies leveraging Tirzepatide's known stability profile.
Cross-batch HPLC fingerprint comparison against the lot-specific COA we publish for every release.

Storage & handling

Tirzepatide arrives lyophilized at −20 °C in cold-chain insulated packaging. On receipt, transfer immediately to a −20 °C freezer. Once reconstituted, store at 2-8 °C and use within the window noted on the lot's COA. Avoid repeated freeze-thaw cycles.

References

Coskun T et al. Mol Metab. 2018;18:3-14.
Frias JP et al. N Engl J Med. 2021;385(6):503-15.
Min T, Bain SC. Diabetes Ther. 2021;12(1):143-57.

For laboratory research only. Tirzepatide is sold strictly as an in-vitro reference standard. It is not approved for human or veterinary use by Health Canada or the FDA.